Investor Overview

Corporate Profile

vTv Therapeutics is a clinical stage biotechnology company committed to improving the lives of diabetes patients.

vTv has a pipeline of clinical drug candidates developed using our innovative technology and led by our TTP399 program for the treatment of type 1 diabetes. vTv’s development partners are pursuing additional indications in type 2 diabetes, chronic obstructive pulmonary disease, psoriasis, atopic dermatitis, renal disease, primary mitochondrial myopathy, and pancreatic cancer.

Corporate Presentation
More >>

Recent News

Date Title
Toggle Summary vTv Therapeutics Announces 2023 Second Quarter Financial Results and Provides Corporate Update
HIGH POINT, N.C. , Aug. 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of cadisegliatin (TTP399) as an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial
View HTML
PDF Version
Toggle Summary vTv Therapeutics Partner Cantex Pharmaceuticals Licenses Exclusive Rights to Intellectual Property from Georgetown University for Azeliragon as a Potential Treatment for Cancer-Related Cognitive Decline
vTv discovered small molecule RAGE inhibitor is being developed by Cantex under worldwide development and commercialization agreement HIGH POINT, N.C. , June 16, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of
View HTML
PDF Version
Toggle Summary vTv Therapeutics Announces Issuance of U.S. Patent for Azeliragon as a Treatment of Glioblastoma to Cantex Pharmaceuticals
vTv discovered small molecule RAGE inhibitor being developed by Cantex under worldwide development and commercialization agreement HIGH POINT, N.C. , May 24, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an
View HTML
PDF Version
Toggle Summary vTv Therapeutics Announces 2023 First Quarter Financial Results and Provides Corporate Update
HIGH POINT, N.C. , May 11, 2023 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a clinical stage biopharmaceutical company focused on the development of an adjunctive therapy to insulin for the treatment of type 1 diabetes ("T1D"), today reported financial results for the first quarter
View HTML
PDF Version
More >>
Upcoming Events
More events are coming soon.

Receive E-mail Alerts

Click here to sign up to receive e-mail alerts whenever vTv Therapeutics Inc. posts new information to the site.

Data Provided by Refinitiv. Minimum 15 minutes delayed.

Stock Quote

(Common Stock)
Exchange (US Dollar)
Price
Change (%)  
Volume
Data as of

Data Provided by Refinitiv. Minimum 15 minutes delayed.